Reset Filters
Branch: 中心馆分拣处

Cover is for reference only

Kinase inhibitor drugs

A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the...

Full description

Saved in:
Bibliographic Details
Main Authors: Li, Rongshi, Ph. D.
Corporate Authors: Wiley InterScience (Online service)
Group Author: Stafford, Jeffrey A.
Published:
Literature type: Electronic eBook
Language: English
Series: Wiley series in drug discovery and development
Subjects:
Protein kinases > Inhibitors > Therapeutic use.
Antineoplastic agents.
MEDICAL > Pharmacology.
Neoplasms > drug therapy.
Protein Kinase Inhibitors > therapeutic use.
Antineoplastic Agents > therapeutic use.
Drug Discovery.
Protein Kinase Inhibitors > pharmacology.
Protein Kinases > metabolism.
Electronic books.
Online Access: http://onlinelibrary.wiley.com/book/10.1002/9780470524961
Summary: A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inh.
Item Description: Includes index.
Carrier Form: 1 online resource.
Bibliography: Includes bibliographical references and index.
ISBN: 9780470524961
0470524960
9780470524954 (electronic bk.)
0470524952 (electronic bk.)
0470278293 (Cloth)
9780470278291 (Cloth)
1282306561
9781282306561
Index Number: RM666
CLC: R977.1
Contents: The discovery and development of sunitinib (SU11248) -- Tykerb discovery : a dual EGFR and erbB2 tyrosine kinase inhibitor -- Discovery of pazopanib, a potent pan vascular endothelial growth factor inhibitor in clinical development -- The road to ABT-869, a multi-targeted receptor tyrosine kinase inhibitor -- Discovery of motesanib -- The discovery of brivanib alaninate, a dual vascular endothelial growth factor and fibroblast growth factor receptor inhibitor -- Structure-based design and characterization of axitinib -- The road to PD0325901 and beyond : the MEK inhibitors quest -- The discovery of allosteric MEK inhibitors -- The discovery of MK-0457 (VX-680) -- Discovery of PHA-739358 -- The discovery of AZD1152 : a selective inhibitor of aurora B kinase with potent anti-tumor activity -- Case study of aurora A inhibitor MLN8054 -- The discovery of GSK461364a -- Pharmacogenomics of dasatinib -- Practical use of computational chemistry in kinase drug discovery -- Approaches to kinase homology modeling : successes and consideration for the structural kinome -- Fragment-based drug discovery of kinase inhibitors -- Protein kinase structural biology : methods and strategies for targeted drug discovery.

Related Book Recommendations